| 시신경척수염 범주 질환에서 리툭시맙 치료 |
|
김수현, 현재원, 김호진 |
|
국립암센터 신경과 |
| Rituximab for the Treatment of Neuromyelitis Optica Spectrum Disorder |
|
Su-Hyun Kim, Jae-Won Hyun, Ho Jin Kim |
|
Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea |
|
|
| Abstract |
|
"Neuromyelitis optica spectrum disorder (NMOSD) is a rare inflammatory autoimmune disorder of the central nervous system that predominantly affects the spinal cord, optic nerve and area postrema.Convergent clinical and laboratory-based investigations have indicated that B cells play a fundamentalrole in NMOSD immunopathology. Accordingly, biologic agents that target B cells are expectedto modulate NMOSD disease activity. Rituximab is a chimeric monoclonal antibody that targetsthe CD20 molecule expressed on the surface of B cells and selectively depleted B cells. Recentretrospective studies suggested robust long-term efficacy and acceptable safety profile of rituximabtherapy in NMOSD. Nevertheless, the place of rituximab in the treatment algorithm of NMOSD, theoptimal dose of rituximab, and the optimal interval for retreatment remain somewhat uncertain.Monitoring rituximab treatment response with CD19+ or CD27+ B cell counts appears to improvetreatment outcomes. In the present review, we describe the state of the art about rituximab treatmentin NMOSD on the literature and authors’ experience and pose questions that would need to be addressedin future studies. Journal of Multiple Sclerosis 8(1):1-8, 2017" |
| Key Words:
Neuromyelitis optica spectrum disorder, Rituximab, B cell |
|
PDF Links
Download Citation
